To access this element change to forms mode OFF
Grant Award View - GA166531
AGITG and Scandinavian Sarcoma Group International Trial Collaboration....
GA ID:
GA166531
Agency:
Department of Health and Aged Care
Approval Date:
24-Mar-2021
Publish Date:
25-May-2021
Category:
Health and Medical Research
Grant Term:
1-May-2021 to 30-Apr-2026
Value (AUD):
$1,036,125.09
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 20/21 1.1 Health Policy Research and Analysis
Grant Program:
2020_MRFF ICTC Round 1_2021
Grant Activity:
AGITG and Scandinavian Sarcoma Group International Trial Collaboration. SSG XXII: International randomised phase III multicenter study of 3 v 5 years of adjuvant imatinib as treatment of patients with operable GIST with high risk for recurrence.
Purpose:
This international trial compares the effect of giving imatinib for 5 years compared the current standard of 3 years to people who have undergone surgery for gastrointestinal stromal tumours (GIST). The aim is to prevent tumours from returning. At present it is not known whether GIST patients benefit from being on treatment for longer than 3 years and half of the participants will be allocated to 2 years extra imatinib. Results could change standards to 5 years or confirm 3 years is optimal.
GO ID:
GO Title:
MRFF Clinical Trial Activity Initiative - 2020 International Clinical Trial Collaborations Grant Opportunity
Internal Reference ID:
MRF2006122
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
Camperdown
Town/City:
Camperdown
Postcode:
2050
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA